Profile: Cell Genesys, Inc. is focused on the development and commercialization of novel biological therapies for cancer patients. GVAX cancer immunotherapies are designed to stimulate a patient's immune system against tumor cells as a means to potentially treat the disease. GVAX cancer immunotherapies are comprised of whole tumor cells that are modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), a potent immune stimulatory cytokine that plays a key role in activating the immune system. The modified cells are irradiated for arresting their growth but remain metabolically active and secrete GM-CSF. Since GVAX cancer immunotherapies are comprised of whole tumor cells, the patient's immune system is presented with multiple antigens. This approach could serve to stimulate a broader and more robust immune response. This in turn could result in greater clinical benefit. GVAX cancer immunotherapies are administered via intradermal injections on an outpatient basis. Our oncolytic virus therapy platform is designed to take the advantage of the adenovirus' (one of the common cold viruses) natural characteristics and to use it in the fight against cancer.